Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

Last updated: February 4, 2025
Sponsor: University of Chicago
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer

Metastatic Cancer

Treatment

Standard of Care

Drug-Gene Interaction Profile

Drug-Drug Interaction Profile

Clinical Study ID

NCT05166694
IRB21-1527
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to determine whether a consultation with a Personalized Therapeutics Clinic, or PTC, will help participants lower the risk for side effects (drug-drug interactions and drug-gene interactions) when taking many medications and help providers improve prescribing decisions for participants. A PTC is a clinical that will test your genes to gather information about your health that may help guide prescribing advice and offer you new information about your prescriptions. Doctors leading this study will look for variations (differences) in your genes that may suggest that you are at greater risk of having side effects or a greater chance of benefiting from certain medications. Individuals in this study will participate for roughly 9 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult participants cared for by a participating provider at University of Chicago Medical Center.

  2. Participants must be at least 18 years of age.

  3. Participants prescribed 5 or medication medications and taking a perpetrator drug or a drug with actionable pharmacogenomic information.

Exclusion Criteria for Participants

  1. Participants who have undergone, or are being actively considered for, liver or kidney transplantation.

  2. Participation in another pharmacogenomic study.

  3. Participants who have previously received genotyping from another source.

  4. Inability to understand and give informed consent to participate.

Inclusion of Women, Minorities, and Other Underrepresented Populations Individuals of all races and ethnic groups and genders are eligible for this trial.

Study Design

Total Participants: 1300
Treatment Group(s): 3
Primary Treatment: Standard of Care
Phase:
Study Start date:
November 30, 2022
Estimated Completion Date:
November 01, 2027

Connect with a study center

  • University of Chicago Medicine

    Chicago, Illinois 60637
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.